REVIEW article
Oncol. Rev.
Sec. Oncology Reviews: Reviews
Volume 19 - 2025 | doi: 10.3389/or.2025.1702932
Liquid Biopsy in Gastrointestinal Oncology: Clinical Applications and Translational Integration of ctDNA, CTCs, and sEVs
Provisionally accepted- 1National Institute of Gastroenterology S. de Bellis Research Hospital (IRCCS), Bari, Italy
- 2Istituto per i Processi Chimico-Fisici Consiglio Nazionale delle Ricerche Unita Organizzativa di Supporto di Bari, Bari, Italy
- 3Universita degli Studi di Bari Aldo Moro Dipartimento di Chimica, Bari, Italy
- 4Universita degli Studi di Parma Dipartimento di Medicina e Chirurgia, Parma, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract. Background & Aims: Liquid biopsy offers a minimally invasive tool to detect actionable mutations, monitor minimal residual disease (MRD), and guide therapy in gastrointestinal (GI) cancers. We critically review the clinical utility of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and small extracellular vesicles (sEVs) across GI malignancies and propose a framework for their integration into clinical practice. Methods: We synthesized evidence from over 200 studies, including prospective trials and translational research, to assess diagnostic accuracy, prognostic value, and clinical actionability of each biomarker type in esophageal, gastric, colorectal, pancreatic, hepatocellular, and biliary cancers. Results: ctDNA has shown strong potential for MRD detection and treatment monitoring, particularly in colorectal and pancreatic cancer. CTCs offer insights into metastatic risk and therapeutic resistance, while sEVs provide molecular cargo relevant to immunomodulation and disease progression. Emerging microfluidics and AI-driven multi-omics approaches may overcome current limitations. Conclusions: The integration of liquid biopsy technologies into GI oncology holds promise for early detection and precision therapy. We propose a five-phase clinical roadmap and outine the key research gaps that need to be addressed before widespread implementation in routine care.
Keywords: liquid biopsy, Gastrointestinal Cancer (GI), Circulating tumor cells (CTC), Extracellular vesicles (EVs), circulating tumor DNA (ctDNA)
Received: 10 Sep 2025; Accepted: 29 Sep 2025.
Copyright: © 2025 Palieri, De Luca, Balestra, Panzetta, Lotesoriere, Rizzi, Ricci, Mastrogiacomo, Curri, Laghi, Giannelli, Depalo and Scavo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Maria Principia Scavo, maria.scavo@irccsdebellis.it
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.